Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals director resigns; Chief Medical Officer's employment ends

Neutral Impact 3 of 5 leadership Written later

Director Richard Lowenthal resigned from the ARS Pharmaceuticals board effective immediately on July 15, 2026, and Chief Medical Officer Sarina Tanimoto, M.D., ceased employment the same day in a termination without cause. The company agreed to one-time payments of $217,350 to Lowenthal and $111,780 to Tanimoto, each a prorated share of their 2026 target bonus, on top of severance described in the 2026 proxy statement. The filing gives no financial results or guidance, but it reports senior leadership departures and added costs.

Key points

  • Richard Lowenthal resigned from the Board effective immediately on July 15, 2026; his resignation was a condition for severance rights.
  • Sarina Tanimoto, M.D., Chief Medical Officer, ceased employment on July 15, 2026, under a termination without cause.
  • One-time payments: $217,350 to Lowenthal and $111,780 to Tanimoto, each a prorated 2026 target bonus.
  • Payments and severance are conditioned on the effectiveness of each executive's release of claims.

The filing

CompanyARS Pharmaceuticals, Inc. (SPRY)
Form8-K, current report
Filed with the SECJul 17, 2026, 4:02 PM ET
Accession number0001193125-26-307773

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.